Related Experiment Video
Updated: Apr 16, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.2K
Devices in heart failure--the new revolution
Sameer Gafoor1, Jennifer Franke, Simon Lam
1CardioVascular Center Frankfurt (CVC), Frankfurt, Germany.
Summary
Heart failure management is evolving. This review details various mechanical circulatory support devices and interventions crucial for patients with persistent symptoms unresponsive to medication.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Devices
Background:
- Heart failure is a growing epidemic, impacting patients who live longer with the disease.
- A significant number of patients experience persistent symptoms despite optimal pharmacologic therapy.
- The scarcity of heart transplant options necessitates advanced therapeutic strategies.
Purpose of the Study:
- To provide a comprehensive overview of current devices and interventions for heart failure.
- To highlight the importance of mechanical circulatory support in managing advanced heart failure.
- To review various device-based treatment options for ventricular dysfunction.
Main Methods:
- Literature review of existing studies and clinical data on heart failure devices.
- Categorization of interventions based on their application (e.g., left vs. right heart, short-term vs. long-term support).
- Analysis of device types including left ventricular reconstruction, aortic counterpulsation, and mechanical circulatory support systems.
Main Results:
- Detailed description of various mechanical circulatory support (MCS) devices.
- Discussion of left ventricular reconstruction and aortic counterpulsation techniques.
- Overview of right heart interventions for heart failure management.
Conclusions:
- Mechanical circulatory support devices are essential for managing heart failure patients with persistent symptoms.
- A range of devices, from short-term to long-term support, are available to assist ventricular function.
- Interventional and device-based therapies are critical in the current landscape of heart failure treatment.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
610
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
610
01:30Heart Failure V: Medical Management
579
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
579
01:30Cardiomyopathy II: Dilated Cardiomyopathy
805
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
627
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
627
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K